| Rituxan (rituximab) / Roche |
2006-005386-19: Cytokines and inflammatory proteins gene expression study in synovial biopsies from rheumatoid arthritis patients refractory to anti-TNF therapy treated with Rituximab |
|
|
| Ongoing | 4 | 20 | Europe | Solution for infusion, MabThera | Cliniques Universitaires Saint-Luc | Rheumatoid arthritis refractory to TNF blockers patients | | | | |
2006-006154-97: HEMOS ALL 0105 Intensification therapy of mature B-ALL, Burkitt and Burkitt like and other HIgh Grade Non-Hodgkinﾒs Lymphoma in Adults |
|
|
| Ongoing | 4 | 25 | Europe | Powder for solution for injection, Tablet, Solution for infusion, Solution for injection, Powder for infusion*, Powder and solvent for solution for injection, Concentrate for solution for infusion, ENDOXAN BAXTER*EV 1FL 500MG, DELTACORTENE FORTE*10CPR 25MG, MABTHERA*EV 1FL 50ML 500MG, DECADRON*10CPR 0,5MG, VINCRISTINA TEVA*IV FL 1MG 1ML, HOLOXAN*EV 1FL 1G, METOTRESSATO TEVA*FL 1G 10ML, VEPESID*EV 1FL 100MG/5ML, VUMON*INFUS 1F 50MG/5ML, ELDISINE*INIET EV FL POLV 5MG, ARACYTIN*IV SC 1FL 500MG+F10ML, CAELYX*INFUS 1FL 2MG/ML 25ML | AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI | B-ALL, Burkitt and Burkitt likeand Non-Hodgkinﾒs Lymphoma in Adults | | | | |
2008-000978-20: Influence de la plasmaphérèse sur la pharmacocinétique du rituximab chez des patients traités pour des pathologies auto immunes. |
|
|
| Ongoing | 4 | 20 | Europe | Solution for injection, MABTHERA | CHU Toulouse | Pathologies auto-immunes | | | | |
ChiCTR-TRC-08000108: Clinical study of Mabthera (Rituximab)+chemotherapy for the treatment in non-Hodgkin's lymphoma (NHL) |
|
|
| Recruiting | 4 | 150 | | EPOCH ;Chemo-treatment ;Chemo-treatment | Fujian Provincial Tumour Hospital; Level of the institution：, Self-supported | Non-Hodgkin's lymphoma (NHL) | | | | |
ChiCTR-TNC-10000798: Rituximab in the treatment of severe lupus myelopathy: a prospective, open-label pilot trial |
|
|
| Completed | 4 | 6 | | Rituximab (MabThera,500mg, intravenously weekly or biweekly for 2-3 times) | Shanghai JiaoTong University School of Medicine Affiliated Renji Hospital; Level of the institution：, Shanghai JiaoTong University School of Medicine Affiliated Renji Hospital | lupus myelopathy | | | | |
ChiCTR-ONC-10001125: The clinical application of rituximabin in treatment of refractory nephrotic syndrome in children |
|
|
| Completed | 4 | 30 | | rituximab 375mg/m2 | Nanjing General hospital of Nanjing militray command; No.305, Zhongshan East Road, Xuanwu District, Nanjing, China, Self-finance | refractory nephrotic syndrome in children | | | | |
| Ongoing | 4 | 180 | Europe | MabThera, RoActemra, L01X CO2, L04AC07, Concentrate for solution for infusion, MabThera, RoActemra | Joint Research & Development Office (Barts and The London School of Medicine & Dentistry), Joint Research & Development Office (Barts and The London School of Medicine & Dentistry) - Queen Mary University London, , Joint Research & Development Office (Barts and The London School of Medicine & Dentistry) - Queen Mary University London, ECAM Clinical Academic Group Barts Health NHS Trust, Joint Research & Development Office (Barts and The London School of Medicine & Dentistry) | Rheumatoid Arthritis, Rheumatoid Arthritis, Diseases [C] - Musculoskeletal Diseases [C05] | | | | |
2014-000859-91: Relation entre la déplétion des LYmphocytes T et la réponse clinique au RITUximab dans la polyarthrite rhumatoïde. Relation entre la déplétion des LYmphocytes T et la réponse clinique au RITUximab dans la polyarthrite rhumatoïde. |
|
|
| Not yet recruiting | 4 | 100 | Europe | Concentrate for solution for infusion, MABTHERA | CHRU de TOURS, CHRU de TOURS | Cette étude portera donc sur une population de patients atteints de polyarthrite rhumatoïde (PR) actives et ayant présenté un échec ou une contre-indication à au moins un anti-TNFα, et n’ayant jamais reçu de rituximab. Cette étude portera donc sur une population de patients atteints de polyarthrite rhumatoïde (PR) actives et ayant présenté un échec ou une contre-indication à au moins un anti-TNFα, et n’ayant jamais reçu de rituximab., Polyarthrite rhumatoïde (PR) Polyarthrite rhumatoïde (PR), Diseases [C] - Immune System Diseases [C20] | | | | |
2015-001807-29: Pharmacokinetic study of rituximab induction regimen in ANCA-associated vasculitis |
|
|
| Not yet recruiting | 4 | 20 | Europe | Rituximab, Concentrate for solution for injection, Rituximab | CHU de Saint-Etienne, THERADIAG | Granulomatosis with polyangiitis Microscopic polyangiitis granulomatose avec polyangéite (GPA) et la polyangéite microscopique (PAM), systemic vasculitis, Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Diagnosis [E01] | | | | |
2004-001199-37: A Phase II, Single Arm, Open label Study of Cyclophosphamide, Vincristine, Liposomal Doxorubicine (Myocet™) and Prednisone plus Rituximab in Fortnightly Regimen (R-COMP-14), as First Line of therapy for Patients with Aggressive Non Hodgkin’s Lymphoma (NHL). |
|
|
| Ongoing | 4 | 75 | Europe | cyclophosphamide, Vincristine, Prednisone, Rituximab, Myocet, Myocet | (GOTEL) Grupo Oncológico para el tratamiento y estudio de los linfomas | Dose-dense modified R-CHOP regimen (R-COMP) in patients with aggressive NHL. | | | | |
2005-000674-43: AN OPEN LABEL STUDY OF THE EFFECT OF TREATMENT WITH RITUXIMAB ON RESISTANT RHEUMATOID ARTHRITIS:Clinical, radiological, synovial and immunological outcomes |
|
|
| Ongoing | 4 | 15 | Europe | Mabthera, N/A, Mabthera, Mabthera | University of Leeds | Rheumatoid Arthritis | | | | |
2005-004582-41: Safety and efficacy of combination treatment with rituximab and leflunomide in patients with active rheumatoid arthritis |
|
|
| Ongoing | 4 | 15 | Europe | Mabthera, Arava, Solu-Medrone 2mg, Rituximab, Leflunomide, Methylprednisolone, Mabthera, Arava, Solu-Medrone 2 Gram, Mabthera, Arava, Solu-Medrone 2 Gram | University of Leeds | Active Rheumatoid Arthritis | | | | |
2005-005110-20: Tratamiento de primera línea del linfoma difuso de célula grande B (LDCGB) con quimioterapia a dosis densas e inmunoterapia (R-CHOP/14) en pacientes mayores de 65 años, y en menores de 65 años de riesgo bajoFirst-line treatment of diffuse large B-cell lymphoma (DLBCL) with dose-dense chemotherpahy and immunotherapy (R-CHOP/14) in patients older than 65 years and in low-risk patients younger than 65 years |
|
|
| Ongoing | 4 | 139 | Europe | Rituximab, Ciclofosfamida, Adriamicina (Doxorubicina), Vincristina, Prednisona, | GEL/TAMO (Grupo Cooperativo Español de Linfoma/Transplante Antólogo de Médula Ósea) | Linfoma difuso de célula grande B (LDCGB)Diffuse large B-cell lymphoma (DLBCL) | | | | |
2007-003623-20: Estudio de los efectos de la terapia anti-célula B (rituximab) sobre la inmunopatología del tejido sinovial y las células B de sangre periférica en artritis reumatoide (Estudio TESICE-AR).Study of the B-cell-targeted therapy (rituximab) effects on the synovial tissue inmunopathology and peripheral blood B cells in rheumatoid arthritis (TESICE-AR study). |
|
|
| Ongoing | 4 | 20 | Europe | Rituximab, Mabthera, Mabthera | Dr. Juan D. Cañete Crespillo, Hospital Clínic de Barcelona | Se estudiaran los efectos de la terapia anti-célula B (rituximab) sobre la inmunopatología del tejido sinovial y las células B de sangre periférica en artritis reumatoide. | | | | |
2008-006342-25: ADMIRE: Does the ADdition of Mitoxantrone Improve REsponse to FCR chemotherapy in patients with CLL: A randomised Phase II Trial of fludarabine, cyclophosphamide and rituximab (FCR) with or without mitoxantrone (M) in previously untreated chronic lymphocytic leukaemia |
|
|
| Ongoing | 4 | 218 | Europe | Rituximab (MabThera), Fludarbine (Fludara Oral), Fludarabine (Fludara), Cyclophosphamide Tablets, Cyclophosphamide injection, Mitoxantrone, MabThera, Mitoxantrone, MabThera, Mitoxantrone | Leeds Teaching Hospitals NHS Trust | Chronic Lymphocytic Leukaemia | | | | |
2009-010998-20: Attenuated dose Rituximab with ChemoTherapy In CLL:A randomised, phase IIB trial in previously untreated patients with Chronic Lymphocytic Leukaemia (CLL) tocompare fludarabine, cyclophosphamide and rituximab (FCR) with FC, mitoxantrone and low dose rituximab (FCM-miniR) |
|
|
| Ongoing | 4 | 206 | Europe | Rituximab (MabThera), Fludarabine (Fludara Oral), Cyclophosphamide Tablets, Fludarabine (Fludara), Mitoxantrone, Rituximab (MabThera or Rituxan) (Reduced dose), Cyclophosphamide injection, MabThera, Mitoxantrone, MabThera, Mitoxantrone | Leeds Teaching Hospitals NHS Trust | Chronic Lymphocytic Leukaemia | | | | |
2009-010955-29: Prevention of clinically manifest rheumatoid arthritis by B cell directed therapy in the earliest phase of the disease. |
|
|
| Ongoing | 4 | 90 | Europe | MabThera 500 mg (10mg/ml), MabThera 500 mg (10mg/ml) | Division of Clinically Immunology and Rheumatology, AMC | Pre-clinical RA patients with a high risk on developing the disease. | | | | |
2008-005450-20: The cost-effectiveness of abatacept, rituximab or anti-TNF alpha for patients with rheumatoid artritis. |
|
|
| Ongoing | 4 | 33 | Europe | Remicade (infliximab), Humira (adalimumab), Enbrel (etanercept), Mabthera (rituximab), Orencia (abatacept), Remicade (infliximab), Humira (adalimumab), Enbrel (etanercept), Mabthera (rituximab), Orencia (abatacept) | Radboud University Nijmegen Medical Centre, department of Rheumatic Diseases | Rheumatoid arthritis | | | | |
2009-016848-39: Evaluation en TEP des modifications du métabolisme cérébral induit par la chimiothérapie RCHOP chez des malades porteurs de lymphome. |
|
|
| Ongoing | 4 | 15 | Europe | GLUCOTEP, GLUCOTEP | CHU Toulouse | lymphome | | | | |
2009-016789-10: Efficacy of the H1N1 Flu (swine flu) vaccination in patients with Rheumatoid Arthritis treated with rituximab |
|
|
| Ongoing | 4 | 90 | Europe | Focetria pandemic influenza vaccine, Pandemrix, Pandemic influenza vaccine, Focetria pandemic influenza vaccine, Pandemrix, Pandemic influenza vaccine | Div KIR AMC | To assess the efficacy of A/H1N1 vaccination in patients treated with rituximab therapy | | | | |
2010-020499-50`ACTRN12620000506998: Changes in bone density and bone turnover in patients with rheumatoid arthritis treated with rituximab, a B cell depleting monoclonal antibody.An investigator-led, industry supported, multicentre, open-label, single treatment arm, prospective clinical trial. |
|
|
| Ongoing | 4 | 46 | Europe | rituximab, MabThera, MabThera | South Tees Hospitals NHS Foundation Trust, Alzheimer's Association | Alzheimer's disease, Mild Cognitive Impairment | | | | |
2011-000905-30: CLINICAL TRIAL WITH PROPHYLACTIC TENOFOVIR FOR HAEMATOLOGICAL CANCER PATIENTS SHOWING A HBc-Ab POSITIVE AND HBs-Ag PATTERN AND TO BE TREATED WITH RITUXIMAB (PREBLIN STUDY) ENSAYO CLÍNICO DE TENOFOVIR EN PROFILAXIS DE PACIENTES HEMATOLÓGICOS ANTI-HBc POSITIVO Y AgHBs NEGATIVO EN TRATAMIENTO CON RITUXIMAB (Estudio PREBLIN) |
|
|
| Ongoing | 4 | 98 | Europe | VIREAD, J05AF07, VIREAD, VIREAD | Rafael Esteban Mur, Gilead Sciences, Inc. | CHRONIC HEPATITIS B HEPATITIS CRÓNICA B | | | | |
2011-000899-33: Rituximab treatment in patients with tjyroid associated that do not respond to intravenous steroids or relapse after intravenous steroid treatment |
|
|
| Ongoing | 4 | 50 | Europe | mabthera, metotrexate, Solu-Medrol, Prednisolon, Mabthera, metotrexate, Solu-Medrol, Prednisolon, Mabthera, metotrexate, Solu-Medrol, Prednisolon | Department of Endocrinology, Sahlgrenska University Hospital | Thyroid associated opthalmopathy | | | | |
2012-005713-39: Reponse to vaccination in patients with bonemarrowcancer who are treated with chemotherapy. Respons op vaccinatie bij patienten met beenmergkanker die behandeld worden met chemotherapie. |
|
|
| Ongoing | 4 | 140 | Europe | Prevnar 13, Influvac or Vaxigrip, RVG 25853, Prevnar 13, Influenza vaccine (Influvac or Vaxigrip), Prevnar 13, Influenza vaccine (Influvac or Vaxigrip) | St. Antonius Hospital, St. Antonius Hospital | multiple myeloma multipel myeloom | | | | |
2016-002908-15: REDO study: Research into the effects of lower doses rituximab in patients with rheumatoid arthritis REDO studie: Onderzoek naar de effecten van lagere doseringen rituximab bij patiënten met reumatoïde artritis |
|
|
| Ongoing | 4 | 140 | Europe | Infusion, MabThera | Sint Maartenskliniek, Menzis, CZ | Rheumatoid arthritis Reumatoïde artritis, Rheumatoid arthritis, chronic inflammation of the joints Reumatoïde artritis, reuma, chronische gewrichtsontsteking, Diseases [C] - Musculoskeletal Diseases [C05] | | | | |
2015-000833-64: Comparaison de trois biomédicaments en termes d’évolution des sous-populations lymphocytaires régulatrices et pro-inflammatoires chez des patients atteints de polyarthrite rhumatoïde. |
|
|
| Not yet recruiting | 4 | 110 | Europe | Powder for concentrate for solution for injection/infusion, Solution for infusion, ORENCIA, MABTHERA, ROACTEMRA | CHU Amiens-Picardie | Rheumatoid arthritis polyarthrite rhumatoïde, Rheumatoid arthritis Polyarthrite rhumatoïde, Diseases [C] - Immune System Diseases [C20] | | | | |
2017-001619-35: Rituximab as first-line therapy in lupus nephritis Rituximab en première ligne thérapeutique dans la néphrite lupique |
|
|
| Ongoing | 4 | 5 | Europe | Solution for injection/infusion, Mabthera | Cliniques Universitaires Saint-lus, Université catholique de Louvain, Cliniques Universitaires saint-Luc, Université catholique de Louvain | Lupus Nephritis Néphrite Lupique, Lupus Nephritis Néphrite Lupique, Diseases [C] - Immune System Diseases [C20] | | | | |
ChiCTR-IPR-15006457: A prospective, multicenter, randomized,double-blind study of mabthera adjuvant therapy in treating ocular adnexal lymphomas |
|
|
| Not yet recruiting | 4 | 140 | | Local radiotherapy and mabthera ;Local radiotherapy and placebo ;CHOP chemotherapy and mabthera ;CHOP chemotherapy and local radiotherapy | Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine; Level of the institution：, Public science and technology research funds project | Ocular adnexal lymphoma | | | | |
| Ongoing | 4 | 52 | Europe | Mabthera, Concentrate for solution for infusion, Mabthera | University College London, Answering TTP Foundation | Acquired thrombotic thrombocytopenic purpura, TTP, Diseases [C] - Blood and lymphatic diseases [C15] | | | | |
2017-002634-24: MultipleMS – a study with the aim to accelerate personalised medicine in multiple sclerosis. MultipleMS - en studie med syftet att utveckla precisionsmedicin för multipel skleros. |
|
|
| Ongoing | 4 | 150 | Europe | Infusion, Capsule, Tablet, Injection, Mabthera, Tysabri, Tecfidera, Gilenya, Copaxone, Betaferon, Extavia, Avonex, Rebif, Plegridy, Lemtrada, Aubagio | Karolinska Institutet, Department of Clinical Neuroscience, Karolinska Institutet | Newly diagnosed patients with Clinically Isolated Syndrome (CIS) and multiple sclerosis (MS) -both relapsing remitting and primary progressive), Multiple sclerosis (MS) is an autoimmune disorder of the central nervous system (CNS), characterized by repeated episodes of inflammation in the CNS leading to various neurological symptoms., Diseases [C] - Nervous System Diseases [C10] | | | | |
| Ongoing | 4 | 800 | Europe | Obinutuzumab, Fludarabine, Fludarabine (IV), Cyclophospamide (oral), Cyclophosphamide (IV), Rituximab, Bendamustine, Mitoxantrone, Alemtuzumab, Ofatumumab, Concentrate for solution for infusion, Film-coated tablet, Powder for solution for infusion, Tablet, Powder for concentrate for solution for infusion, Concentrate and solvent for solution for infusion, Obinutuzumab, Fludarabine (oral), Ofatumumab | University of Leeds, Napp Pharmaceuticals | Chronic lymphocytic leukaemia (CLL), Chronic lymphocytic leukaemia (CLL), Diseases [C] - Cancer [C04] | | | | |
ChiCTR-OPC-16008628: Chidamide with Rituximab for Relapsed/Refratory Germinal Center subtype of Diffuse Large B Cell Lymphoma |
|
|
| Recruiting | 4 | 20 | | Chidamide with Rituximab | Qilu Hospital， Shandong University; Level of the institution：, none | Germinal center subtype of Diffuse Large B Cell Lymphoma | | | | |
ChiCTR1800020142: The clinical study on the efficacy and safety of CDOP regimen with pegylated liposomal doxorubicin ± rituximab in the treatment of diffuse large B-cell lymphoma |
|
|
| Recruiting | 4 | 300 | | PLD 25 mg/ m2，iv，d1，cyclophosphamide 750 mg/m2, vincristine 1.4 mg/m2, up to 2 mg, or vindesine 3 mg/m2, intravenously (iv.) all on day 1; and prednisone 100 mg orally on days 1 to 5, with or without rituximab 375 mg/m2, iv. on day 0, administered every 21 days (n=304) for six or eight cycle | Beijing Cancer Hospital; Beijing Cancer Hospital, CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. | diffuse large B-cell lymphoma | | | | |
ChiCTR-OPC-16010056: The efficacy and safety of R-EPOCH and R-CHOP regimen for patients with AIDS associated CD20+ diffuse large B lymphoma |
|
|
| Recruiting | 4 | 50 | | R-EPOCH regimen treatment ;R-CHOP regimen treatment | Shanghai Public Health Clinical Center; 上海市金山区漕廊公路2901号, Medical Science Support Program by Shanghai Science and Technology Committee | AIDS-associated CD20+ diffuse large B lymphoma | | | | |
2018-003588-69: The ENDURRANCE-1 Study. Exploring durable remission with rituximab in ANCA associated vasculitis |
|
|
| Not yet recruiting | 4 | 44 | Europe | Cyclophosphamide, 5009111000001105, Powder for infusion, Cyclophosphamide | Leiden University Medical Center, LUMC leiden | ANCA associated vasculitis ANCA geassocieerde vasculitis, Small vessel vasculitis kleine vaten vasculitis, Diseases [C] - Immune System Diseases [C20] | | | | |
2019-001754-25: Using adalimumab serum concentration to choose a subsequent biological treatment in rheumatoid arthritis patients failing adalimumab treatment |
|
|
| Not yet recruiting | 4 | 84 | Europe | Etanercepet, Rituximab, Abatacept, Tocilizumab, Sarilumab, Injection, Enbrel, Benepali, Erelzi Rituximab: mabthera, Rixathon, Truxima Abatacept: Orencia Tocilizumab: Roactemra Sarilumab: Kevzara | Reade, ZonMw | rheumatoid arthritis, Rheumatoid arthritis, Diseases [C] - Immune System Diseases [C20] | | | | |
| Active, not recruiting | 4 | 140 | Japan | Rituximab, Rituxan, Glucocorticoids, Predonine, Prednisolone | Chiba University | Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, Microscopic Polyangiitis, Wegener Granulomatosis | 12/19 | 06/21 | | |
ChiCTR-IPR-16008631: A randomized controlled study of comparing the efficacy and safety of Pegylated liposmal doxorubicin, Epirubicin and Doxorubicin in Diffuse large B cell lymphoma |
|
|
| Not yet recruiting | 4 | 225 | | R-CDOP protocol ;R-CEOP protocol ;R-CHOP protocol | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology; Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, self-finacing | Diffuse large B cell lymphoma | | | | |
NCT02378298: Rituximab (RTX) Therapy in Patients With Active TAO |
|
|
| Active, not recruiting | 4 | 26 | Europe | Rituximab, Mabthera, Rituxan, Zytux, L01XC02, Iv Methylprednisolone, Solumedrol, peroral methylprednisolone and Methotrexate, Prednisolone | Göteborg University, Sahlgrenska University Hospital, Sweden | Ophthalmopathy, Thyroid-Associated | 02/20 | 12/24 | | |
ChiCTR1800014960: Rituximab in the treatment of EBV infection and post-transplantation lymphoproliferative diseases after allogeneic hematopoietic stem cell transplantation: a multicenter, prospective, clinical study |
|
|
| Recruiting | 4 | 30 | | Rituximab | Shanghai Children's Medical Center affiliated to Shanghai Jiao Tong University School of Medicine; Shanghai Children's Medical Center affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai Children's Medical Center affiliated to Shanghai Jiao Tong University School of Medicine | EBV Infection | | | | |
ChiCTR1800020022: A multicenter, One-arm, Open, Prospective study for Low-dose Lenalidomide plus Rituximab (Laili) Regimen in the treatment of Elderly or Relapsed/Refractory B-cell non-Hodgkin's Lymphoma |
|
|
| Not yet recruiting | 4 | 100 | | low dose of lenalidomide and rituximab | The Affiliated Cancer Hospital of Zhengzhou University/Henan Cancer Hospital; The Affiliated Cancer Hospital of Zhengzhou University/Henan Cancer Hospital, self-financed | B-cell non-Hodgkin's lymphoma | | | | |
2020-002507-19: Research into administration of lower dosed rituximab with an injection Onderzoek naar het toedienen van lagere doseringen rituximab via een injectie |
|
|
| Not yet recruiting | 4 | 36 | Europe | rituximab, Solution for injection, Concentrate for solution for infusion, MabThera, Rixathon | Sint Maartenskliniek, Sint Maartenskliniek | rheumatoid arthritis reumatoïde artritis, rheumatic disease reuma, Diseases [C] - Musculoskeletal Diseases [C05] | | | | |
| Active, not recruiting | 4 | 100 | Europe | Rituximab, Mabthera, Tacrolimus, Advagraf, Adoport, Prograf, Mycophenylate mofetil, MMF, Cellcept, Hydrocortisone, Prednisolone | Guy's and St Thomas' NHS Foundation Trust, Astellas Pharma Europe Ltd. | Function of Renal Transplant | 10/20 | 10/22 | | |
|
ChiCTR-IPR-16008527: Rituximab in the treatment of refractory membranous nephropathy: a multicenter, randomized, controlled clinical study |
|
|
| Completed | 4 | 180 | | oral CsA and glucosteroid ;intravenous RTX ;Intravenous cyclophosphamide and glucosteroid | Ruijin Hospital, affiliated to Shanghai Jiaotong University, School of medicine; Ruijin Hospital, affiliated to Shanghai Jiaotong University, School of medicine, Multi-center research funding of Shanghai Jiaotong University School of Medicine | Membranous nephropathy | | | | |
ChiCTR1900020916: A Clinical study for low dose Dectabine + R-CHOP treat diffuse large B cells lymphoma |
|
|
| Recruiting | 4 | 20 | | low dose Dac+R-CHOP ;R-CHOP | Anhui Provincial Cancer Hospital; Anhui Provincial Cancer Hospital, Anhui province department of finance appropriation | Diffuse Large B Cells Lymphoma | | | | |
2021-000710-42: Research into the effect of the COVID-vaccine in patients who are treated with rituximab (RTX-COVAC study) Onderzoek naar het effect van de COVID-vaccinatie bij patiënten die behandeld worden met rituximab (de RTX-COVAC studie). |
|
|
| Ongoing | 4 | 270 | Europe | COVID-19 Vaccine Moderna, COVID-19 Vaccine AstraZeneca, Concentrate for solution for injection, Dispersion for injection, Suspension for injection, Comirnaty, COVID-19 Vaccine Moderna, COVID-19 Vaccine AstraZeneca | Sint Maartenskliniek, Sint Maartenskliniek | Rheumatoid arthritis Reumatoïde artritis, Rheumatic disease Reuma, Diseases [C] - Musculoskeletal Diseases [C05] | | | | |
ChiCTR2000035408: A randomized controlled study for rituximab in first-line treatment of newly diagnosed immune thrombocytopenia |
|
|
| Recruiting | 4 | 60 | | Rituximab (Hanrikang) 375mg/m2, 4 times a week (day 8, 15, 22, 29). ;Rituximab (Hanrikang) 100mg/ time once a week, administered 4 times (day 8, 15, 22 and 29). ;high-dose dexamethasone (HD-DXM), 40mg/d, iv for 4 days (day 1 to day 4), every 15 days, 2 to 4 cycles, until CR or the end of the study. | Henan Cancer Hospital; Henan Cancer Hospital, Jiangsu fosun pharmaceutical sales co. LTD | Idiopathic Thrombocytopenic Purpura | | | | |
NCT04542629: Comparative Study of Dietary and Immunological Management of Refractory Epilepsy in Children |
|
|
| Not yet recruiting | 4 | 140 | NA | RiTUXimab Injection [Rituxan], KETOGENIC DIET, TRACE ELEMENTS, CORTICOSTEROID INJECTION | Assiut University | Refractory Epilepsy | 08/21 | 08/22 | | |
ChiCTR1800017001: Precision Medicine Study about Drug Effect and Adverse Reaction of Rituximab in lymphonma Treatment Based on Metabonomics, Pharmacogenomics and Gut Microbiota. |
|
|
| Recruiting | 4 | 200 | | none | Sun Yat-Sen University Cancer Center; Sun Yat-Sen University Cancer Center, National Natural Science Foundation of China (81730103,81573507), Hospital Pharmacy Fundation of Guangdong | B cell lymphoma | | | | |
ChiCTR1900026380: Rituximab plus Lenalidomide in elderly untreated patients with DLBCL |
|
|
| Recruiting | 4 | 60 | | Rituximab plus Lenalidomide | Anhui Provincial Cance Hospital; Anhui Provincial Cance Hospital, Self-collected | DLBCL | | | | |
ChiCTR2000033540: Prospective Randomized Trial on Efficacy of Rituximab Combined Therapy and Supportive Therapy on Early-Stage Non-Nephrotic Primary Membranous Nephropathy |
|
|
| Recruiting | 4 | 38 | | Rituximab 600mg iv, and supportive treatment ;Supportive treatment according to KDIGO guideline | Peking Union Medical College Hospital, Chinese Academy of Medical Sciences; Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Self-supporting | Membranous Nephropathy | | | | |
| Terminated | 4 | 115 | US | Rituximab, Rituxan | Massachusetts General Hospital | Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | 01/22 | 01/22 | | |
NCT04518475: Eltrombopag Combining Rituximab Versus Eltrombopag in the Management of Primary Immune Thrombocytopenia (ITP) in Adults |
|
|
| Recruiting | 4 | 224 | RoW | eltrombopag combining rituximab, TPO-R agonist & anti-CD20 antibody, eltrombopag, TPO-R agonist | Institute of Hematology & Blood Diseases Hospital, The Second Affiliated Hospital of Kunming Medical University, Henan Cancer Hospital, Tianjin Medical University Second Hospital, The First Affiliated Hospital of Xiamen University, Nantong University | Primary Immune Thrombocytopenia (ITP) | 02/22 | 08/22 | | |
NCT05191225: Ultrafast Truxima Infusion in Non-Hodgkin's Lymphoma: Txagorapid Study |
|
|
| Recruiting | 4 | 48 | Europe | RiTUXimab Injection [Truxima] | Laida Cuevas Palomares | Non-Hodgkin's Lymphoma | 03/22 | 12/22 | | |
ChiCTR2000040799: Prospective study of rituximab combined with low-dose hormone in the treatment of idiopathic membranous nephropathy |
|
|
| Recruiting | 4 | 50 | | Rituximab | The First Affiliated Hospital, Sun Yat-Sen University; The First Affiliated Hospital, Sun Yat-Sen University, self-raised | idiopathic membranous nephropathy | | | | |
ChiCTR2000033337: R-BAC regimen in the treatment of relapsed and refractory diffuse large B-cell lymphoma |
|
|
| Not yet recruiting | 4 | 50 | | Rituximab, Bendamustine combined with Cytarabine | Xiangya Second Hospital of Central South University; Xiangya Second Hospital of Central South University, Self-raised | Relapsed and refractory diffuse large B-cell lymphoma | | | | |
ChiCTR2000036318: A prospective phase II multicenter clinical study of rituximab combined with local radiotherapy in the treatment of newly diagnosed early mucosa-associated lymphoid tissue lymphoma |
|
|
| Not yet recruiting | 4 | 60 | | rituximab combined with local radiotherapy | Anhui Provincial Cance Hospital; Level of the institution：, Self-collected | mucosa-associated lymphoid tissue lymphoma | | | | |
ChiCTR2300070327: Efficacy of novle prednisone-premedication R-CHOP protocol vs. standard R-CHOP regimen in the prevention of rituximab-related reactions in newly-diagnosed diffuse large B cell lymphoma: A multicenter randomized controlled study |
|
|
| Completed | 4 | 88 | | prednisone-premedication R-CHOP protocol ;standard R-CHOP regimen | Jiujiang University Affiliated Hospital; Jiujiang University Affiliated Hospital, None | diffuse large B cell lymphoma | | | | |
| Not yet recruiting | 4 | 80 | | rituximab ;tacrolimus | Xinqiao Hospital; Xinqiao Hospital, The science and technology innovation ability enhancement special project of The Army Medical University | membranous nephropathy | | | | |
ChiCTR1900025744: Clinical effectiveness and safety of Rituximab (Henlius) for optic neuritis secondary to neuromyelitis optica spectrum disorder: a pilot clinical trial |
|
|
| Recruiting | 4 | 60 | | Intravenous 200mg Rituximab, 1/week*2, if the proportion of CD19+ B lymphocytes in peripheral blood is above 1% then repeat administration (200mg) ;Oral azathioprine (2.5-3 mg/kg bodyweight/day) or mycophenolate mofetil (750～3000mg/day) | The Ophthalmology Department of the Chinese Peoples Liberation Army Hospital; The General Hospital of Chinese Peoples Liberation Army, funded by the National Natural Science Fundation of China (NO.81870662) | neuromyelitis optica spectrum disorder （NMOSD） | | | | |
| Active, not recruiting | 4 | 290 | RoW | Rituximab, Cyclophosphamide, Epirubicin, Vincristine, Prednisone | Ruijin Hospital | Diffuse Large B-cell Lymphoma | 10/22 | 12/24 | | |
ChiCTR2000039456: A single arm and prospective clinical trial of zanubrutinib plus R-CHOP in untreated double expression diffuse large B-Cell Lymphoma with international prognostic index equal or greater than 2 scores |
|
|
| Recruiting | 4 | 49 | | zanubrutinib plus R-CHOP | West China Hospital, Sichuan University; West China Hospital, Baiji Shenzhou Biotechnology Co., Ltd | double expressing diffuse large B-cell lymphoma | | | | |
ChiCTR1900026382: Low dose rituximab driven by B cell count for nephrotic syndrome: a multi-center prospective cohort study |
|
|
| Completed | 4 | 105 | | Rituximab | Jiangsu Province People's Hospital; Jiangsu Province People's Hospital, Jiangsu Province Kidney Disease Clinical Research Center program (BL 20100080) | nephrotic syndrome | | | | |
ChiCTR2000030603: A multicenter prospective cohort clinical study of a short-course glucocorticoid therapy regimen for glucocorticoid-dependent immune thrombocytopenia |
|
|
| Recruiting | 4 | 390 | | treat with glucocorticoid ;treat with eltrombopag ;treat with rituximab ;treat with splenectomy ;treat with azathioprine ;treat with cyclosporine | The Second Affiliated Hospital of Kunming Medical University; The Second Affiliated Hospital of Kunming Medical University, The Second Affiliated Hospital of Kunming Medical University | Primary Immune Thrombocytopenia | | | | |
NCT04127747: Efficacy of Individualized Rituximab in Maintaining Remission of Moderate and Severe Systemic Lupus Erythematosus |
|
|
| Recruiting | 4 | 110 | RoW | Standard dose of rituximab, Individualized dose of rituximab | Second Affiliated Hospital, School of Medicine, Zhejiang University | Autoimmune Diseases | 12/22 | 07/23 | | |
ChiCTR2100042674: Standard dose Rituximab for membranous nephropathy: a multi-center prospective cohort study |
|
|
| Recruiting | 4 | 65 | | RTX treatment | Jiangsu Province People's Hospital; Jiangsu Province People's Hospital, Jiangsu Province Kidney Disease Clinical Research Center program (BL 20100080) | syndrome disease | | | | |
NCT06134284: Clinical Study of OR for Second-line Treatment of Refractory MZL |
|
|
| Recruiting | 4 | 39 | RoW | Orelabrutinib combined with rituximab | Lixia Sheng | OR Regimen for Relapsed/Refractory Marginal Zone Lymphoma | 12/26 | 12/29 | | |
ChiCTR2100046611: Prospective cohort study of rituximab combined with low dose hormone in the treatment of refractory nephrotic syndrome |
|
|
| Recruiting | 4 | 50 | | Rituximab | The First Affiliated Hospital, Sun Yat-Sen University; The First Affiliated Hospital, Sun Yat-Sen University, self-raised | Difficult-to-treat nephropathy syndrome | | | | |
ChiCTR2100042513: A prospective, open, single center clinical study to evaluate the efficacy of rituximab combined with zebutinib in the treatment of elderly patients with central nervous system lymphoma |
|
|
| Recruiting | 4 | 20 | | rituximab combined with zanubrutinib | Jiangsu Cancer Hospital; Jiangsu Cancer Hospital, Self-collected | CNSL | | | | |
ChiCTR2100046400: A prospective randomized controlled study of rituximab combined with radiotherapy for active thyroid-associated ophthalmopathy patients not sensitive to intravenous glucocorticoids shock therapy |
|
|
| Recruiting | 4 | 80 | | Radiotherapy combined with rituximab ;Radiotherapy | the Ninth People's Hospital, Shanghai Jiaotong University School of Medicine; The Ninth People's Hospital Affiliated to Shanghai Jiaotong University School of Medicine, self-funded | thyroid associated ophthalmopathy | | | | |
NCT04842318: Rituximab Maintenance Treatment of Newly Diagnosed Follicular Lymphoma After BR or RCHOP or R2: a Multicenter Clinical Study |
|
|
| Recruiting | 4 | 789 | RoW | BR for 6 cycles +R for 8 cycles, RCHOP for 6 cycles +R for 8 cycles, R2 for 6 cycles + R2 maintenance | Ruijin Hospital | Follicular Lymphoma | 03/23 | 03/24 | | |
NCT04083066: Open Randomized Prospective Clinical Study of R-FPD Versus R-MAD Regimen in the Treatment of Primary Central Nervous System Lymphoma |
|
|
| Recruiting | 4 | 20 | RoW | rituximab in combination with methotrexate, cytarabine and dexamethasone | Mingzhi Zhang | Primary Central Nervous System Lymphoma | 04/23 | 04/24 | | |
ChiCTR1900027748: A single-arm multicenter prospective clinical study of rituximab 500 mg/m2 in glucocorticoid-ineffective or glucocorticoid-dependent primary immune thrombocytopenia |
|
|
| Recruiting | 4 | 60 | | Rituximab (500mg/m2, once intravenously) | Department of Hematology, the Second Affiliated Hospital of Kunming Medical University; the Second Affiliated Hospital of Kunming Medical University, the Second Affiliated Hospital of Kunming Medical University | Primary Immune Thrombocytopenia | | | | |
ChiCTR2000031963: A single-center prospective study of rituximab in the treatment of adult refractory nephrotic syndrome |
|
|
| Recruiting | 4 | 50 | | Rituximab treatment; routine regimen | 万启军; Department of Nephrology, Shenzhen Second People's Hospital, Shenzhen Second People’s Hospital | Adult refractory nephrotic syndrome | | | | |
| Recruiting | 4 | 116 | RoW | Rituximab, HLX01, RAS 2410, No specific restrictions | CHENNAN, Dongfang Hospital Affiliated to Tongji University, Shanghai Pudong New Area People's Hospital, Ruijin Hospital North Shanghai Jiao Tong University School of Medicine, Ningbo Municipal Yinzhou District No.2 Hospital, Third Affiliated Hospital, Sun Yat-Sen University, Xiamen Hongai Hospital, Sir Run Run Shaw Hospital | IgA Nephropathy | 07/23 | 12/23 | | |
| Recruiting | 4 | 12 | | Conventional therapy ;Rituximab | Guangzhou Women and Children Medical Center; Guangzhou Women and Children Medical Center, Natural Science Foundation of China | biliary atresia | | | | |
ChiCTR2000036468: A Multicentre, Randomized, Controlled Trial of Rituximab in Treatment of Primary IgA Nephropathy |
|
|
| Recruiting | 4 | 116 | | Rituximab+RASi ;RASi | Ruijin Hospital, Shanghai Jiaotong University School of Medicine; Shanghai East Hospital, Fosun Pharmaceutical Distribution Jiangsu. Co., Ltd. | IgAN | | | | |
NCT05824390: A Randomized, Controlled Clinical Study of Rituximab in Treatment of Primary IgA Nephropathy |
|
|
| Active, not recruiting | 4 | 116 | RoW | rituximab group, ACEi and / or ARB | XIEJINGYUAN, Dongfang Hospital Affiliated to Tongji University, Shanghai Pudong New Area People's Hospital, Ruijin Hospital North Shanghai Jiao Tong University School of Medicine, Ningbo Municipal Yinzhou District No.2 Hospital, Third Affiliated Hospital, Sun Yat-Sen University, Xiamen Hongai Hospital, Sir Run Run Shaw Hospital | IgA Nephropathy | 10/23 | 10/23 | | |
ChiCTR2100051890: Efficacy and safety analysis of Tetrasip in refractory primary immune thrombocytopenia |
|
|
| Not yet recruiting | 4 | 60 | | Telitacicept ;Eltrombopag ;Rituximab | The Second Affiliated Hospital of Kunming Medical University; The Second Affiliated Hospital of Kunming Medical University, Regional Science Foundation Project | Primary Immune Thrombocytopenia | | | | |
NCT02382575: Efficacy and Safety of Rituximab to That of Calcineurin Inhibitors in Children With Steroid Resistant Nephrotic Syndrome |
|
|
| Recruiting | 4 | 120 | RoW | Rituximab, anti CD20 monclonal antibody, Tacrolimus, Calcineurin inhibitor | Nilratan Sircar Medical College | Nephrotic Syndrome | 12/23 | 12/23 | | |
ChiCTR2200055483: A clinical study on the efficacy and safety of R-CHOP/BR+Zanubrutinib in the first-line treatment of young mantle cell lymphoma |
|
|
| Recruiting | 4 | 20 | | R-CHOP/BR+zanubrutinib | The First Affiliated Hospital of Soochow University; The First Affiliated Hospital of Soochow University, Beigene, Ltd. | N/A | | | | |
ChiCTR2100043013: Efficacy difference between low dose rituximab and mycophenolate mofetil in preventing recurrence of NMOSD |
|
|
| Not yet recruiting | 4 | 60 | | low dose rituximab ;mycophenolate mofetil | Shandong University Qilu Hospital; Shandong University Qilu Hospital, self-finance | Neuromyelitis optica spectrum diseases | | | | |
| Recruiting | 4 | 200 | RoW | GlucoCorticoid, Rituximab, Cyclophosphamide | Wang Mo | Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, ANCA-Associated Glomerulonephritis | 12/23 | 12/25 | | |
| Recruiting | 4 | 467 | RoW | Dexamethasone, Prednisolone and Azathioprine, Rituximab, Eltrombopag, Romiplostim | Nahda University | Immune Thrombocytopenia Purpura | 01/24 | 04/24 | | |
| Recruiting | 4 | 15 | RoW | Rituximab, Belimumab | Peking Union Medical College Hospital, Children's Hospital of Chongqing Medical University, Central South University, Shenzhen Children's Hospital, The First Hospital of Jilin University, Children's Hospital of The Capital Institute of Pediatrics, The Affiliated Hospital of Qingdao University, Children's Hospital of Nanjing Medical University, Children's Hospital of Fudan University, Shengjing Hospital, Shanghai Children's Hospital, Tianjin Children's Hospital | Sjogren's Syndrome, Pediatric ALL | 12/25 | 12/26 | | |
ChiCTR2200062766: Long-term efficacy, safety and immunological parameters of individualized rituximab regimen for the treatment of pemphigus |
|
|
| Recruiting | 4 | 86 | | Individualized rituximab regimen (the initial dose is 100mg, and 1 month later for those peripheral blood B cells are not depleted will be given 500mg，and 1 month later for those peripheral blood B cells are still not depleted will be given 1000mg ). ;Conventional dosage of glucocorticoid 【for patients with severe pemphigus (PDAI＞45): 1.5mg/kg/d，for patients with moderate pemphigus （15≤PDAI≤45）: 1mg/kg/d ，for patients with mild pemphigus（PDAI＜15）:0.5mg/kg/d】 | Peking University First Hospital; Peking University First Hospital, None | Pemphigus | | | | |
ChiCTR2300073448: Clinical study of mitoxantrone hydrochloride liposome injection combined with rituximab and bendamustine (RMB) in the treatment of relapsed/refractory diffuse large B-cell lymphoma (DLBCL): a single-arm, single-center, prospective phase Ib |
|
|
| Not yet recruiting | 4 | 12 | | Different doses of mitoxantrone hydrochloride liposome injection and fixed doses of rituximab, bendamustine | Chongqing University Cancer Hospital; Chongqing University Cancer Hospital, none | Relapsed and refractory diffuse large B-cell lymphoma | | | | |
ChiCTR2100048742: Treatment responses of azathiopurine, mortimecofenate, rituximab and IVIg in children with relapsing myelin oligodendrocyte glycoprotein antibody–associated disease |
|
|
| Recruiting | 4 | 200 | | azathiopurine ;rituximab ;mortimecofenate ;gamma globulin | Department of Pediatrics, Peking University First Hospital; Peking University First Hospital, No | MOG-IgG associated disease | | | | |
ChiCTR2100048364: A single-arm, prospective, and multicenter study of rituximab combined with lenalidomide in Castleman disease |
|
|
| Not yet recruiting | 4 | 20 | | Rituximab+lenalidomide | Department of Hematology, Jiangsu Provincial People's Hospital; Jiangsu Provincial People's Hospital, National Natural Science Foundation of China | Castleman disease | | | | |
ChiCTR2300072920: An open single arm clinical study of combination of anti-PD-1 monoclonal antibody and R-CHOP for de novo CD5+ diffuse large B-cell lymphoma |
|
|
| Recruiting | 4 | 20 | | anti-PD-1 monoclonal antibody and R-CHOP | Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University; Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University, Beijing Medical Award Foundation | diffuse large B cell lymphoma | | | | |
ChiCTR2100053056: One arm prospective clinical study of zebutinib combined with R-CHOP regimen induced bridging autologous hematopoietic stem cell transplantation in the treatment of newly diagnosed extranodal diffuse large B-cell lymphoma |
|
|
| Recruiting | 4 | 40 | | Bridging autologous hematopoietic stem cell transplantation induced by zebutinib combined with R-CHOP regimen | Chongqing University Cancer Hospital; Chongqing University Cancer Hospital, Hainan Shanglin Sunshine Medical Development Foundation | Lymphoma | | | | |
| Recruiting | 4 | 50 | RoW | Rituximab, Hanlikang | Chinese SLE Treatment And Research Group | Systemic Lupus Erythematosus, Pulmonary Arterial Hypertension | 03/25 | 03/26 | | |
ChiCTR2200062467: The treatment of prednisolone combined with rituximab in patients with minimal change nephropathy: A multicenter randomized controlled clinical trial |
|
|
| Not yet recruiting | 4 | 72 | | Prednisolone combined with rituximab ;Prednisolone only | Peking University First Hospital; Peking University First Hospital, Jiangsu Fosun Pharmaceutical Sales Co., Ltd | Minimal change disease | | | | |
| Not yet recruiting | 4 | 36 | | Rituximab | The First Hospital of China Medical University; The First Hospital of China Medical University, Shenyang Science and Technology Plan Project Public Health R&D Special Project | Systemic lupus erythematosus | | | | |
ChiCTR2200063452: Clinical study of RCHOP combined with Zanubrutinib regimen in DLBCL of MCD subtype |
|
|
| Not yet recruiting | 4 | 40 | | None | The First Affiliated Hospital, College of Medicine, Zhejiang University; The First Affiliated Hospital, College of Medicine, Zhejiang University, Self-faised funds | Diffuse large B-cell lymphoma | | | | |
NCT05514015: Clinical Study of Rituximab Combined With Corticosteroids or Rituximab Monotherapy in the Treatment of Primary Membranous Nephropathy |
|
|
| Recruiting | 4 | 78 | RoW | rituximab combined with corticosteroids, Intervention arm, rituximab, Control arm | First Affiliated Hospital, Sun Yat-Sen University | Primary Membranous Nephropathy | 09/26 | 12/26 | | |
ChiCTR2100050955: A single-arm, single-center clinical study of rituximab therapy in AAGN-induced remission |
|
|
| Recruiting | 4 | 20 | | Rituximab therapy during induction of AAGN | Pediatric Hospital Affiliated to Fudan University; Pediatric Hospital Affiliated to Fudan University, Self-funded | ANCA-associated glomerulonephritis | | | | |
Origin, ChiCTR2300077256 : Orelabrutinib combined with rituximab for the treatment of elderly patients with newly diagnosed non-GCB diffuse large B-Cell lymphoma under the guidance of genetic subtype: A prospective , multicenter, single-arm, response-adaptive clinical study |
|
|
| Recruiting | 4 | 63 | | Study combined miniCHOP after induction of OR Orelabrutinib 150mg QD d1-21, Ruximab 375mg / m2 d1) | The First Affiliated Hospital of Zhejiang University Medical College |
Diffuse large B-cell Lymphoma | | | | |
ChiCTR2100054244: A single-center observational study on the efficacy and safety of rituximab in adult patients with minimal change nephropathy |
|
|
| Recruiting | 4 | 100 | | No ;No | Shenzhen Second People's Hospital; Shenzhen Second People's Hospital, Shenzhen Second People's Hospital | Minimal change nephropathy of adult | | | | |
ChiCTR2100054552: “Efficacy and safety of Zanubrutinib in combination with R-CHOP in newly diagnosed non-GCB DLBCL patients who are PET positive after two cycles of R-CHOP treatment: a single-arm, open-label, prospective follow-up study |
|
|
| Recruiting | 4 | 44 | | RCHOP combined with Zanubrutinib | West China Hospital of Sichuan University; West China Hospital of Sichuan University, BeiGene (Beijing) Biotechnology Co., Ltd. | Diffuse large B-cell lymphoma (DLBCL) | | | | |